Researchers from Janssen Research & Development presented promising interim results from the Phase 3 MMY3004 (CASTOR) clinical trial, assessing the immunotherapy drug daratumumab (Darzalex) against standard of care…
News
Celgene Corporation recently presented a study comparing overall survival, treatment patterns, and healthcare costs between Caucasian (white-skinned) and African-American Medicare beneficiaries who were diagnosed with multiple…
The Multiple Myeloma Research Foundation (MMRF) has announced that its founder, Kathy Giusti, has been appointed faculty co-chair of the Harvard Business School (HBS)…
Researchers at the University of Louisville and collaborators from Japan and Austria have identified a protein called AF1q whose expression may predict the development of an…
Researchers at Buffalo, New York’s Roswell Park Cancer Institute (RPCI) have showed that maintenance lenalidomide (marketed as Revlimid) following autologous hematopoietic stem cell (HSC) transplant improves…
In a poster presentation at the 2016 ASCO Annual Meeting in Chicago, MorphoSys presented updated safety and efficacy data from an ongoing open-label, multicenter, Phase…
The Moffitt Cancer Center has completed a Phase 1 clinical trial of selinexor combined with liposomal doxorubicin and dexamethasone for the treatment of…
The European Commission (EC) has granted provisional approval to Janssen’s Darzalex (daratumumab) as a monotherapy for the treatment of patients with multiple myeloma who…
An immune-based vaccine created by researchers at Buffalo, New York’s Roswell Park Cancer Institute (RPCI) is now moving to its third study. The new…
Iceni Pharmaceuticals, formerly known as Big DNA Ltd., announced plans to soon begin testing its lead product Cilcane (cilengitide) as a first-in-class treatment for multiple…
